Cardiology23 Jul 2026
Factor XIa Inhibitors After Heart Attack: A New Antithrombotic Path?Read article
Cardiology23 Jul 2026
GLP-1 Agonists: Do They Prevent Heart Disease in the General Population?Read article
The Life Science Feed
Deep dives with clinicians, researchers, and industry leaders.
All episodesARHGAP36: A new survival predictor for neuroblastoma patients
High ARHGAP36 levels predict improved 5-year survival in neuroblastoma patients, linking FOXC1-induced expression to altered Hedgehog signaling.
The real reason joint oncology practices need explicit protocols
Running a joint oncology clinic presents unique challenges and benefits, requiring careful navigation of professional boundaries and patient dynamics.
Forget sterile tumors: Cancers house unique microbiomes
A comprehensive analysis of over 17,000 tumor samples confirms distinct microbial signatures across 35 cancer types, influencing prognosis and treatment response.
Cancer survival improves. Why are rural outcomes still worsening?
Sitting for Long Stretches Linked to Higher Cancer Mortality Risk
Molecular Profiling Refines Salivary Gland Tumor Diagnosis
Jideytro offers new hope for ROS1-positive NSCLC after prior therapy
Metastatic pancreatic cancer: A new drug could shift your approach
How non-animal models are redefining oncology drug safety
EHR-derived marker flags liver transplant recipients at high risk of early death
An EHR-based marker identifies liver transplant recipients at increased risk of 90-day mortality, offering a tool for pre-transplant risk stratification and post-operative management.
EHR data flags liver transplant patients at highest risk of post-op complications
An EHR-based marker identifies liver transplant recipients at high risk for adverse post-transplant outcomes, offering a tool for early intervention and personalised care strategies.
Liver Transplant Studies Retracted Over Organ Harvesting Concerns
Multiple liver transplant studies have been retracted from major medical journals due to concerns over the ethical sourcing of donor organs, raising serious questions about research integrity.
EHR data identifies liver transplant patients at high risk of early graft loss
Chronic Hepatitis Delta Virus: Why direct viral targeting matters now
Metabolic Dysfunction Associated Steatotic Liver Disease: An Overview
Liver-Directed Treatment Shows Efficacy in Metabolic Dysfunction
TNF emerges as a key node in autoimmune hepatitis, trial shows
Nearly 1 in 10 With Primary Biliary Cholangitis Have CKD
Pulsed Field Ablation: A New Frontier for Atrial Fibrillation?
Pulsed field ablation offers a novel, non-thermal approach to cardiac tissue destruction, leveraging irreversible electroporation for targeted cell death in arrhythmias.
Heart Failure Treatment in 2026: A Clinical Overview
Heart failure management has changed substantially over the past decade. This clinical overview covers the four pillars of guideline-directed medical therapy, the role of device therapy, and emerging treatments entering practice in 2026.
How lipid packing dictates caveolae stability at the plasma membrane
Lipid packing density plays a critical role in confining caveolae to the plasma membrane, influencing their stability and function in cellular processes.
Severe VT in ischaemic cardiomyopathy: Why current care isn't enough
Cardiovascular risk: Why men die earlier, women live sicker
Smartphones and Pacemakers: Separating Fact from Electromagnetic Fiction
For atrial fibrillation, integrated pathways may beat individual fixes
Why cardiac amyloidosis diagnoses are surging and what it means for GPs
A Simpler Score for Coronary Calcium: Does it Help Predict Risk?
What Is an SGLT2 Inhibitor? Mechanism, Indications, and Evidence
SGLT2 inhibitors block renal glucose reabsorption to lower blood sugar and protect the heart and kidneys. A clinical primer on mechanism, approved agents, key trial evidence, and safety.
GLP-1s and lifestyle: a new path to stronger bones?
Combining GLP-1 receptor agonists with lifestyle interventions may offer benefits for bone mineral density, particularly in patients with obesity.
Setmelanotide curbs insatiable hunger in acquired hypothalamic obesity
Setmelanotide significantly improved body mass index, hunger, and hyperphagia symptoms in patients with acquired hypothalamic obesity, according to the TRANSCEND trial.
CGM offers tighter glucose control for type 2 diabetes on dialysis
Metabolic Syndrome: Is it accelerating your patients' brain aging?
Tzield expands its reach: A new option for recently diagnosed pediatric type 1 diabetes
Your obesity patients deserve more than just weight loss goals
Why lifestyle advice alone still dominates obesity searches
Weekly growth hormone therapy: a safer path to long-term height gains?
Repeated head impacts: What they mean for dementia risk
Repeated blows to the head in contact sports significantly increase the risk of dementia, particularly in former professional athletes.
Katie Couric's Transient Global Amnesia: A 'Big, Black Hole' Event
Katie Couric recently described an episode of transient global amnesia, a sudden, temporary loss of memory that can be alarming but is typically benign.
Vitamin C's cognitive promise clashes with new clinical data
Vitamin C supplementation does not improve cognitive function in healthy adults. Advanced MRI reveals previously undetectable MS lesions, while new criteria define profound autism.
Roche Halts Huntington's Gene-Silencing Programs
The long shadow of head trauma: sport, CTE, and dementia risk
Chronic Migraine: Is the Gut-Brain Axis the Missing Link?
Ecopipam for Tourette Syndrome: Did it deliver on its promise?
Football Headers Linked to Cognitive Decline, Neurodegeneration
Beyond screen time: How short videos rewire dopamine pathways
Multiple MyelomaThe Neutropenic Diet: An Unnecessary Burden for Leukemia and Transplant Patients?
Get the full storyRNR inhibition reverses FLT3i resistance in AML, prolonging survival
Get the full storyAsciminib: A new first-line option for chronic myeloid leukemia?
Get the full storyWhat Is CAR-T Cell Therapy? Mechanism, Approved Indications, and Key Evidence
Get the full storyDonor T-cells prevent CMV complications in blood cancer patients
Get the full storyMAHA Monday: The Rush to Publish and Its Clinical Fallout
Get the full storyLiso-Cel Delivers Durable OS Benefit in R/R LBCL, Redefining Treatment
Get the full storyNew Regimen Confers 'Meaningful' Benefit in Aggressive Lymphoma
Get the full storyFDA Expands Casgevy for Sickle Cell in Children 2 Years and Older
Get the full storyMonoclonal Antibodies May Complicate Transfusion Testing
Get the full story
Arthritis RheumatoidInterrupting immunomodulators for infection: a strategy without evidence?
Get the full storyMissing early psoriatic arthritis means irreversible joint damage
Get the full storyFrailty, not just RA, predicts osteoporotic fracture risk
Get the full storyEnpatoran gets breakthrough tag for lupus: Another IFN-I inhibitor enters the fray
Get the full storyMicrobiome's Role in Lupus: A Policy and Therapeutic 'Frame Shift'
Get the full storySleep Disruption and Fear Drive Chronic Rheumatic Pain
Get the full storyWhy Cheaper Humira Alternatives Face Resistance
Listen nowStopping Spinal Fusion Or Protecting The Gut?
Listen nowChasing Absolute Zero In Rheumatoid Arthritis
Listen nowThe ORAL Surveillance JAK Inhibitor Controversy
Listen now
Lung NeoplasmsCryoprobe Biopsy Improves Diagnostic Yield in Transbronchial Biopsy
Get the full storyAir Embolism: Two Cases After Percutaneous Lung Biopsy
Get the full storySingle Question May Flag Poor Quality Sleep in Patients
Get the full storyPembrolizumab Reduces Pulmonary AEs vs Chemotherapy in NSCLC
Get the full storyDupilumab Superior to Omalizumab in High-Biomarker Asthma
Get the full storyATS 2026: NTM Lung Disease Detection, Therapy, QoL Advancements
Get the full storyBRINSUPRI® First Therapy Approved for NCFB at ATS 2026
Get the full storyEpithelial Cytokines Link Severe Asthma, CRSwNP, COPD at ATS 2026
Get the full storyTriple Therapy in Asthma: Real-World Evidence Supports Earlier Use
Get the full storyYUTREPIA® (treprostinil) Inhalation Powder for PH-ILD Patients
Get the full story
Drug Resistance MicrobialBundibugyo virus: Why community trust is the only vaccine we have
Get the full storyInfluenza treatment: The single-dose option challenges multi-day adherence
Get the full storyScrewworm EUA: How targeting larval development changes prevention
Get the full storyTreating screwworm: Why an OTC generic is now the frontline
Get the full storyThe antibiotic paradox: More drugs won't solve resistance
Get the full storyMeningitis B: Why campus life shifts vaccine guidance for your patients
Get the full storyBlack Death Survivors' Genetic Legacy Offers Clues for COVID-19 Resilience
Get the full storyLong COVID: Objective Biomarkers Challenge Psychosomatic Narrative
Get the full storyNew Virus Catalogue Identifies Top Pathogen Threats to Human Health
Get the full storySodium Fluoroacetate Offers Hope Against Australia's Mouse Plagues
Get the full story
Dermatitis AtopicDoes dupilumab increase lymphoma risk in eczema patients?
Get the full storyPeptide Therapies: Decoding Evidence from Topicals to Longevity
Get the full storyDermatomyositis Guidelines Identify Cancer Risk
Get the full storyLitfulo Label Strengthened With New Alopecia Areata Safety Warnings
Get the full storyFDA Rejects Galderma's RelabotulinumtoxinA for Second Time
Get the full storyCAR T-Cell Therapy Nears Approval for Refractory Skin Diseases
Get the full storyTSW Controversy: Mitochondrial NAD Excess Identified, Diagnostic Clarity Emerges
Get the full storyPrior Authorization Delays Atopic Dermatitis Treatment Access
Get the full storyPatient-Reported Factors Redefine Alopecia Areata Severity
Get the full storyScalp Lesions: Rare Malignancies Mimic Benign Conditions
Get the full storyThe largest unmet need in cardiology finally has a multi-drug evidence base
Amivantamab plus lazertinib vs osimertinib: a survival benchmark four years in the making
Resmetirom changed everything. Now the race is on for combination therapies and broader eligibility
12 FDA-approved JAK inhibitors, updated EULAR guidelines, and the TYK2 era beginning
From G12C to pan-RAS: the mutation-by-mutation guide to the KRAS revolution
• Aug 28 – 31ERS 2026 • Barcelona, ES 
• Sep 5 – 9EASD 2026 • Milan, IT 
• Sep 28 – Oct 2UEG Week 2026 • Vienna, AT 
• Oct 3 – 7Joint ACTRIMS-ECTRIMS 2026 • Toronto, CA 
• Oct 21 – 23ESMO 2026 • Madrid, ES • Oct 23 – 27AHA 2026 • Chicago, US 
• Nov 7 – 9ACR 2026 • Washington DC, US • Nov 14 – 19ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12ESC 2026 • Munich, DE • Aug 28 – 31ERS 2026 • Barcelona, ES • Sep 5 – 9EASD 2026 • Milan, IT • Sep 28 – Oct 2UEG Week 2026 • Vienna, AT • Oct 3 – 7Joint ACTRIMS-ECTRIMS 2026 • Toronto, CA • Oct 21 – 23ESMO 2026 • Madrid, ES • Oct 23 – 27AHA 2026 • Chicago, US • Nov 7 – 9ACR 2026 • Washington DC, US • Nov 14 – 19ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12
BostonJun 13 – 16 2026
XLH Adults: Osteomalacia Persists Despite Conventional Therapy
Adults with X-linked hypophosphatemia (XLH) frequently experience persistent osteomalacia, even with conventional phosphate and active vitamin D treatment.
Afirma Molecular Testing: Unique Situations and New Prognostic Development
Afirma molecular testing aids thyroid nodule management, particularly in indeterminate cytology. New prognostic markers enhance risk stratification.
GLP-1 RAs Reduce CV Risk in T2D Via Weight, Glucose Pathways
GLP-1 receptor agonists offer cardiovascular risk reduction in type 2 diabetes through both weight loss and direct glucose-lowering mechanisms.
Defining Hyperphagia Treatment Possibilities in Prader-Willi Syndrome
Clinician and caregiver perspectives highlight the complex challenges and unmet needs in managing hyperphagia in Prader-Willi Syndrome.
Liver-Directed Treatment Shows Efficacy in Metabolic Dysfunction
A novel liver-directed treatment presented at endo 2026 offers a targeted approach for metabolic dysfunction, addressing a significant unmet clinical need.
Hypoparathyroidism Treatment: Patient, Care Partner, HCP Perspectives
New perspectives on hypoparathyroidism treatment from patients, care partners, and HCPs highlight unmet needs and treatment goals.
Severe Hypoglycemia in T1D: Enhancing Patient-Clinician Dialogue
Addressing severe hypoglycemic events in type 1 diabetes requires direct, empathetic clinician-patient conversations to improve management and outcomes.
Endocrinologists' Role in Early Thyroid Eye Disease Recognition
Early recognition of thyroid eye disease (TED) by endocrinologists is critical for optimal patient outcomes, enabling timely intervention.
Classic CAH: New Approaches to Glucocorticoid Dosing
Endocrinology specialists are re-evaluating glucocorticoid dosing strategies for classic congenital adrenal hyperplasia (CAH), focusing on individualised regimens to balance androgen control and minimise adverse effects.
Low Alkaline Phosphatase: Recognizing Clinical Consequences
Low alkaline phosphatase (ALP) is often overlooked, but its clinical consequences, particularly hypophosphatasia, warrant increased diagnostic vigilance.
Desmopressin Dosing Refined for Central Diabetes Insipidus
New insights into desmopressin administration for central diabetes insipidus (CDI) aim to optimise efficacy and minimise hyponatremia risk.
Acromegaly Management: Focus on Biochemical Control at ENDO 2026
New insights from ENDO 2026 highlight the persistent challenges in achieving biochemical control for acromegaly patients.
12 Months of Romosozumab Builds Bone Density in Postmenopausal Osteoporosis
A 12-month course of romosozumab significantly increases bone mineral density in postmenopausal women with osteoporosis.
Desiccated Thyroid Extract: Efficacy and Safety in Hypothyroidism
A case-based discussion at endo 2026 reviewed the role of desiccated thyroid extract (DTE) in hypothyroidism management, highlighting patient selection and comparative efficacy.
Steroidogenesis Inhibitor Targets Root Cause of Cushing’s Syndrome
A novel steroidogenesis inhibitor presented at ENDO 2026 offers a targeted approach to endogenous Cushing's syndrome by reducing cortisol overproduction.
Peer Insights on Once-Daily Weight Management Therapy at endo 2026
Endocrinology specialists discussed the clinical utility of a once-daily treatment for weight management in appropriate adult patients.
Hypothyroidism: Symptom Burden Persists Despite Euthyroidism
Many patients with hypothyroidism report persistent symptoms despite achieving biochemical euthyroidism, highlighting a significant symptom-treatment gap.
Endo 2026: Risk-Based Osteoporosis Management Refines Clinical Practice
Endo 2026 highlighted refined risk-based strategies for osteoporosis care, advocating for tailored interventions beyond universal guidelines to improve patient outcomes.
Hypercortisolism: Emerging Diagnostic and Management Insights
New evidence presented at Endo 2026 refines our understanding of hypercortisolism, impacting diagnostic strategies and therapeutic approaches.
Obesity Care: Tailored Treatment Strategies Highlighted at endo 2026
Personalised treatment approaches for obesity, moving beyond a 'one-size-fits-all' model, were a key focus at endo 2026.
Cushing's Syndrome: Addressing Diagnostic Delays and Treatment Gaps
Cushing's syndrome presents a diagnostic challenge, often leading to significant delays in treatment initiation and suboptimal patient outcomes.
Korlym® for Cushing's Syndrome: Patient Experience, Side Effects and 2026 Clinical Data
Patient-reported outcomes from Endo 2026 show Korlym® (mifepristone) cuts weight gain, fatigue and mood disturbances in Cushing's syndrome. Covers mechanism of cortisol receptor blockade, side effect profile, and how it compares to relacorilant.
XLH Adults: Osteomalacia Persists Despite Conventional Therapy
Adults with X-linked hypophosphatemia (XLH) frequently experience persistent osteomalacia, even with conventional phosphate and active vitamin D treatment.
Afirma Molecular Testing: Unique Situations and New Prognostic Development
Afirma molecular testing aids thyroid nodule management, particularly in indeterminate cytology. New prognostic markers enhance risk stratification.
GLP-1 RAs Reduce CV Risk in T2D Via Weight, Glucose Pathways
GLP-1 receptor agonists offer cardiovascular risk reduction in type 2 diabetes through both weight loss and direct glucose-lowering mechanisms.
Defining Hyperphagia Treatment Possibilities in Prader-Willi Syndrome
Clinician and caregiver perspectives highlight the complex challenges and unmet needs in managing hyperphagia in Prader-Willi Syndrome.
Liver-Directed Treatment Shows Efficacy in Metabolic Dysfunction
A novel liver-directed treatment presented at endo 2026 offers a targeted approach for metabolic dysfunction, addressing a significant unmet clinical need.
Hypoparathyroidism Treatment: Patient, Care Partner, HCP Perspectives
New perspectives on hypoparathyroidism treatment from patients, care partners, and HCPs highlight unmet needs and treatment goals.
Severe Hypoglycemia in T1D: Enhancing Patient-Clinician Dialogue
Addressing severe hypoglycemic events in type 1 diabetes requires direct, empathetic clinician-patient conversations to improve management and outcomes.
Endocrinologists' Role in Early Thyroid Eye Disease Recognition
Early recognition of thyroid eye disease (TED) by endocrinologists is critical for optimal patient outcomes, enabling timely intervention.
Classic CAH: New Approaches to Glucocorticoid Dosing
Endocrinology specialists are re-evaluating glucocorticoid dosing strategies for classic congenital adrenal hyperplasia (CAH), focusing on individualised regimens to balance androgen control and minimise adverse effects.
Low Alkaline Phosphatase: Recognizing Clinical Consequences
Low alkaline phosphatase (ALP) is often overlooked, but its clinical consequences, particularly hypophosphatasia, warrant increased diagnostic vigilance.
Desmopressin Dosing Refined for Central Diabetes Insipidus
New insights into desmopressin administration for central diabetes insipidus (CDI) aim to optimise efficacy and minimise hyponatremia risk.
Acromegaly Management: Focus on Biochemical Control at ENDO 2026
New insights from ENDO 2026 highlight the persistent challenges in achieving biochemical control for acromegaly patients.
12 Months of Romosozumab Builds Bone Density in Postmenopausal Osteoporosis
A 12-month course of romosozumab significantly increases bone mineral density in postmenopausal women with osteoporosis.
Desiccated Thyroid Extract: Efficacy and Safety in Hypothyroidism
A case-based discussion at endo 2026 reviewed the role of desiccated thyroid extract (DTE) in hypothyroidism management, highlighting patient selection and comparative efficacy.
Steroidogenesis Inhibitor Targets Root Cause of Cushing’s Syndrome
A novel steroidogenesis inhibitor presented at ENDO 2026 offers a targeted approach to endogenous Cushing's syndrome by reducing cortisol overproduction.
Peer Insights on Once-Daily Weight Management Therapy at endo 2026
Endocrinology specialists discussed the clinical utility of a once-daily treatment for weight management in appropriate adult patients.
Hypothyroidism: Symptom Burden Persists Despite Euthyroidism
Many patients with hypothyroidism report persistent symptoms despite achieving biochemical euthyroidism, highlighting a significant symptom-treatment gap.
Endo 2026: Risk-Based Osteoporosis Management Refines Clinical Practice
Endo 2026 highlighted refined risk-based strategies for osteoporosis care, advocating for tailored interventions beyond universal guidelines to improve patient outcomes.
Hypercortisolism: Emerging Diagnostic and Management Insights
New evidence presented at Endo 2026 refines our understanding of hypercortisolism, impacting diagnostic strategies and therapeutic approaches.
Obesity Care: Tailored Treatment Strategies Highlighted at endo 2026
Personalised treatment approaches for obesity, moving beyond a 'one-size-fits-all' model, were a key focus at endo 2026.
Cushing's Syndrome: Addressing Diagnostic Delays and Treatment Gaps
Cushing's syndrome presents a diagnostic challenge, often leading to significant delays in treatment initiation and suboptimal patient outcomes.
Korlym® for Cushing's Syndrome: Patient Experience, Side Effects and 2026 Clinical Data
Patient-reported outcomes from Endo 2026 show Korlym® (mifepristone) cuts weight gain, fatigue and mood disturbances in Cushing's syndrome. Covers mechanism of cortisol receptor blockade, side effect profile, and how it compares to relacorilant.
